NCT00479349已完成1 期
An Ascending Multiple Dose Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Japanese Young Male and Elderly Subjects
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 32 人开始时间: 2007年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 主要终点
- Safety and tolerability
研究概览
简要总结
To assess the safety and tolerability of ascending multiple oral doses of SAM-531, an investigational drug, in healthy Japanese young male and elderly subjects.To provide the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of multiple oral doses of SAM-531 in healthy Japanese young male and elderly subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 —(Adult, Older Adult)
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Active Comparator
SAM 531 + placebo
干预措施: SAM-531 (Drug)
结局指标
主要结局
Safety and tolerability
时间窗: 9 months
次要结局
- Pharmacokinetics and pharmacodynamics(9 months)
研究者
相似试验
已完成
1 期
Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly SubjectsAlzheimer DiseaseNCT00480818Wyeth is now a wholly owned subsidiary of Pfizer80
终止
1 期
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315Alzheimer DiseaseNCT00474552Wyeth is now a wholly owned subsidiary of Pfizer56
已完成
1 期
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese MalesAlzheimer DiseaseNCT00479297Wyeth is now a wholly owned subsidiary of Pfizer72
已完成
1 期
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy SubjectsAlzheimer DiseaseNCT00479700Wyeth is now a wholly owned subsidiary of Pfizer80
已完成
1 期
Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy AdultsAlzheimer DiseaseNCT00479440Wyeth is now a wholly owned subsidiary of Pfizer56
